Social and economic consequences of the influence of bronchospasm on health of children and adolescents in the context of public health management improvement

Economic Annals-ХХI: Volume 193, Issue (9-10), Pages: 134-145

Citation information:
Geppe, N., Farber, I., Polyanskaya, A., Chebysheva, S., & Aksenova, M. (2021). Social and economic consequences of the influence of bronchospasm on health of children and adolescents in the context of public health management improvement. Economic Annals-XXI, 193(9-10), 134-145. doi: https://doi.org/10.21003/ea.V193-17


Natalya Geppe
D.Sc. (Medical Science),
Professor,
Head, Department of Children’s Diseases,
N. F. Filatov Clinical Institute of Children’s Health,
I. M. Sechenov First Moscow State Medical University of Health of the Russian Federation (Sechenov University)
2/4 Bolshaya Pirogovskaya Str., Moscow, 119435, Russian Federation
geppe@mail.ru
ORCID ID: https://orcid.org/0000-0003-0547-3686

Irina Farber
PhD (Medical Science),
Assistant,
Department of Children’s Diseases,
N. F. Filatov Clinical Institute of Children’s Health,
I. M. Sechenov First Moscow State Medical University of Health of the Russian Federation (Sechenov University)
2/4 Bolshaya Pirogovskaya Str., Moscow, 119435, Russian Federation
imfarber@gmail.com
ORCID ID: https://orcid.org/0000-0001-6919-6732

Angelina Polyanskaya
PhD (Medical Science),
Associate Professor of the Department of Children’s Diseases,
N. F. Filatov Clinical Institute of Children’s Health,
I. M. Sechenov First Moscow State Medical University of Health of the Russian Federation (Sechenov University)
2/4 Bolshaya Pirogovskaya Str., Moscow, 119435, Russian Federation
meleshkina.angel@mail.ru
ORCID ID: https://orcid.org/0000-0002-4125-0335

Svetlana Chebysheva
PhD (Medical Science),
Associate Professor of the Department of Children’s Diseases,
N. F. Filatov Clinical Institute of Children’s Health,
I. M. Sechenov First Moscow State Medical University of Health of the Russian Federation (Sechenov University)
2/4 Bolshaya Pirogovskaya Str., Moscow, 119435, Russian Federation
svetamma@gmail.com
ORCID ID: https://orcid.org/0000-0001-5669-4214

Marianna Aksenova
PhD (Medical Science),
Associate Professor of the Department of Hospital Therapy No. 1,
I. M. Sechenov First Moscow State Medical University of Health of the Russian Federation (Sechenov University)
2/4 Bolshaya Pirogovskaya Str., Moscow, 119435, Russian Federation
axenovamarianna@mail.ru
ORCID ID: https://orcid.org/0000-0003-4802-6544

Social and economic consequences of the influence of bronchospasm on health of children and adolescents in the context of public health management improvement

Abstract. The health status of the population as an integral indicator is a part of the socially-oriented policy of the state, which reflects the degree of its social development and the state of ensuring the quality of public health. It is determined that the current demographic situation in Russia is accompanied by a rapid deterioration in the health of the population and reduction in the number of people of working age for the reason of premature mortality which inevitably causes a decline in human capital. Losses significantly affect the economic, social and intellectual potential of the country. High cost of medical services, dissatisfaction with the quality and limited access to medical care do not meet the interests of the state, patients, and medical service providers.

In this regard, the purpose of our paper is to analyze the impact of bronchospasm in children as a peculiar disease that requires medical treatment and otherwise influences future population health and social and economic indicators on the country’s economy and to study the impact of this widespread diseases on the overall economic and socio-economic situation in the country taking into account comparison and indicators from different countries of the world.

It has been concluded that to achieve set health goals in public health and reduce negative health impact, international and national public and private partnerships should be promoted.

Keywords: Public Health; Economics; Cost; Medical Service; Quality; Treatment; Bronchospasm; Bronchial Asthma; Physical Activity; Children; Adolescents; Education; PPP

JEL Classіfіcatіon: I10; P46

Acknowledgements and Funding: The authors received no direct funding for this research.

Contribution: The authors contributed equally to this work.

Data Availability Statement: The dataset is available from the authors upon request.

DOI: https://doi.org/10.21003/ea.V193-17

References

  1. Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alsahali, S., Alrasheedy, A. A., Martin, A. P., Godman, B., & Alfadl, A. A. (2020). Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India. Pharmaco Economics, 4, 331-342.
    https://doi.org/10.1007/s41669-019-0172-x
  2. Arokiasamy, P., Uttamacharya, U., Jain, K. et al. (2015). The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Medicine, 13, 178.
    https://doi.org/10.1186/s12916-015-0402-8
  3. Bähler, C., Huber, C. A., Brüngger, B., & Reich, O. (2015). Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC Health Services Research, 15, 23.
    https://doi.org/10.1186/s12913-015-0698-2
  4. Blanc, P. D., Annesi-Maesano, I., Balmes, J. R. et al. (2019). The occupational burden of non-malignant respiratory diseases. An official American Thoracic Society and European Respiratory Society Statement. American Journal of Respiratory and Critical Care Medicine, 199(11), 1312-1334.
    https://doi.org/10.1164/rccm.201904-0717st
  5. Cohen, S. B. (2012). The concentration of health care expenditures and related expenses for costly medical conditions, 2012. Statistical Brief # 455 (Medical Expenditure Panel Survey (US)). Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality.
    https://www.ncbi.nlm.nih.gov/books/NBK470837
  6. Ehteshami-Afshar, S., FitzGerald, J. M., Doyle-Waters, M. M., & Sadatsafavi, M. (2016). The global economic burden of asthma and chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease, 20(1), 11-23.
    https://doi.org/10.5588/ijtld.15.0472
  7. Ford, E. S., Murphy, L. B., Khavjou, O., Giles, W. H., Holt, J. B., & Croft, J. B. (2015). Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest, 147(1), 31-45.
    https://doi.org/10.1378/chest.14-0972
  8. Gibson, G. J., Loddenkemper, R., Lundback, B., & Sibille, Y. (2013). Respiratory health and disease in Europe: the new European Lung White Book. European Respiratory Journal, 42, 559-563.
    https://doi.org/10.1183/09031936.00105513
  9. Global Initiative for Chronic Obstructive Lung Disease. (2020). Global Strategy for Prevention Diagnosis and Management of Chronic Obstructive Pulmonary Disease 2020 Report.
    https://goldcopd.org/gold-reports
  10. Gutiérrez Villegas, C., Paz-Zulueta, M., Herrero-Montes, M., Parás-Bravo, P., & Madrazo Pérez, M. (2021). Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Economics Review, 11, 31.
    https://doi.org/10.1186/s13561-021-00329-9
  11. Kalchiem-Dekel, O., Galvin, J., Burke, A. P., Atamas, S., & Todd, N. (2018). Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. Journal of Clinical Medicine, 7(12), 476.
    https://doi.org/10.3390/jcm7120476
  12. Maqhuzu, Ph. N., Kreuter, M., Bahmer, Th., Kahn, N., Claussen, M., Holle, R., & Schwarzkopf, L. (2021). Cost drivers in the pharmacological treatment of interstitial lung disease. Respiratory Research, 22, 218.
    https://doi.org/10.1186/s12931-021-01807-8
  13. Maselli, D. J., Keyt, H., & Restrepo, M. I. (2017). Inhaled antibiotic therapy in chronic respiratory diseases. International Journal of Molecular Sciences, 18(5), 1062.
    https://doi.org/10.3390/ijms18051062
  14. Menzella, F., Lusuardi, M., Galeone, C., & Facciolongo, N. (2017). Bronchial thermoplasty and the role of airway smooth muscle: Are we on the right direction? Therapeutics and Clinical Risk Management, 13, 1213-1221.
    https://doi.org/10.2147/TCRM.S144604
  15. Schroeder, M., Benjamin, N., Atienza, L., Biswas, C., Martin, A., Whalen, J. D., Izquierdo Alonso, J. L., Riesco Miranda, J. A., Soler-Cataluña, J. J., Huerta, A., & Ismaila, A. S. (2020). Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. International Journal of Chronic Obstructive Pulmonary Disease, 15, 1621-1632.
    https://doi.org/10.2147/COPD.S240556
  16. Slim, D., Gunawardena, H., Calvert, J. M., Daly, R. S., Plummeridge, M. J., & Medford, A. R. (2018). IgG4-related pulmonary disease: The protean impersonator? Journal of the Royal College of Physicians of Edinburgh, 48(2), 130-133.
    https://doi.org/10.4997/jrcpe.2018.207
  17. Yang, G., Wang, Y., Zeng, Y., Gao, G. F., Liang, X., Zhou, M. et al. (2013). Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. The Lancet, 381, 1987-2015.
    https://doi.org/10.1016/S0140-6736(13)61097-1
  18. Zhang, Y., Li, S., Li, Y., et al. (2007). Analysis of the use of medicine in the fixed medical institution’s clinics of the New Rural Cooperative Medical System. Med Philos 27, 42-3.

Received 16.03.2021
Received in revised form 19.05.2021
Accepted 2.06.2021
Available online 19.10.2021